| HOME >> BIOLOGY >> TECHNOLOGY |
"The diagnosis of ALS can take up to a year, and many patients are initially misdiagnosed with another condition," said Jeff Weisberg, vice president and general manager for Athena Diagnostics. "We believe C9orf72 testing has the potential to significantly enhance the quality and speed of diagnosis for many patients under evaluation for this disorder."
"We applaud Steve Gleason and Team Gleason for generating public awareness of ALS and the need for improved medical advances for this disease," said Weisberg.
The C9orf72 testing service will be available to clinicians for ALS and FTD as a standalone offering and in multi-gene evaluations on April 30. Athena Diagnostics now offers genetic testing services for identifying eight other genes associated with ALS. Together, these genes account for up to 70% of familial ALS. The Company recommends genetic counseling for patients and their family before any genetic test is ordered.
About Athena Diagnostics
Founded in 1988, Athena Diagnostics is the leading provider of advanced diagnostic testing services for neurological disorders, including dementia, epilepsy, developmental disorders, motor neuron disorders, and neuromuscular disorders. Based in Worcester, Massachusetts, Athena provides the most comprehensive specialty test menu through more than 350 tests in the areas of neurology, endocrinology, and nephrology. Quest Diagnostics acquired Athena from Thermo Fisher Scientific in April 2011. For more information, visit
| SOURCE Quest Diagnostics Copyright©2010 PR Newswire. All rights reserved |